Skip to main content
Top
Published in: Virology Journal 1/2008

Open Access 01-12-2008 | Short report

Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1

Authors: Angeline PC Lim, Steven KK Wong, Annie HY Chan, Conrad EZ Chan, Eng Eong Ooi, Brendon J Hanson

Published in: Virology Journal | Issue 1/2008

Login to get access

Abstract

The monoclonal antibody VN04-2 was previously shown to protect mice against lethal A/Vietnam/1203/04 H5N1 virus challenge when administered pre- and post-infection. In this study, we characterized the binding requirements of this antibody using direct binding to hemagglutinin and neutralization assays with H5N1 virus-like particles (H5N1-VLP) of eight recent H5N1 strains representing the major mutations within the 140s antigenic loop. Binding was clade independent and 3 mutations within this antigenic region are required before escape is possible, suggesting that apart from the H5N1 viruses circulating in Indonesia, VN04-2 may provide protection against H5N1 viruses from all other regions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998, 351: 472-477. 10.1016/S0140-6736(97)11212-0.CrossRefPubMed Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998, 351: 472-477. 10.1016/S0140-6736(97)11212-0.CrossRefPubMed
2.
go back to reference de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL: A pandemic warning?. Nature. 1997, 389: 554-10.1038/39218.CrossRefPubMed de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL: A pandemic warning?. Nature. 1997, 389: 554-10.1038/39218.CrossRefPubMed
3.
go back to reference Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, Cheung PT, To WK, Ho ET, Sung R, Cheng AF: Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998, 351: 467-471. 10.1016/S0140-6736(98)01182-9.CrossRefPubMed Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, Cheung PT, To WK, Ho ET, Sung R, Cheng AF: Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998, 351: 467-471. 10.1016/S0140-6736(98)01182-9.CrossRefPubMed
4.
go back to reference Fouchier R, Kuiken T, Rimmelzwaan G, Osterhaus A: Global task force for influenza. Nature. 2005, 435: 419-420. 10.1038/435419a.CrossRefPubMed Fouchier R, Kuiken T, Rimmelzwaan G, Osterhaus A: Global task force for influenza. Nature. 2005, 435: 419-420. 10.1038/435419a.CrossRefPubMed
5.
go back to reference Webster RG, Govorkova EA: H5N1 influenza–continuing evolution and spread. N Engl J Med. 2006, 355: 2174-2177. 10.1056/NEJMp068205.CrossRefPubMed Webster RG, Govorkova EA: H5N1 influenza–continuing evolution and spread. N Engl J Med. 2006, 355: 2174-2177. 10.1056/NEJMp068205.CrossRefPubMed
7.
go back to reference Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, et al: Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007, 4: e178-10.1371/journal.pmed.0040178.PubMedCentralCrossRefPubMed Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, et al: Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007, 4: e178-10.1371/journal.pmed.0040178.PubMedCentralCrossRefPubMed
8.
go back to reference Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ: Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res. 2006, 7: 126-10.1186/1465-9921-7-126.PubMedCentralCrossRefPubMed Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ: Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res. 2006, 7: 126-10.1186/1465-9921-7-126.PubMedCentralCrossRefPubMed
9.
go back to reference Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X: Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respiratory Research. 2006, 7: 43-10.1186/1465-9921-7-43.PubMedCentralCrossRefPubMed Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X: Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respiratory Research. 2006, 7: 43-10.1186/1465-9921-7-43.PubMedCentralCrossRefPubMed
10.
go back to reference Zhou B, Zhong N, Guan Y: Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007, 357: 1450-1451. 10.1056/NEJMc070359.CrossRefPubMed Zhou B, Zhong N, Guan Y: Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007, 357: 1450-1451. 10.1056/NEJMc070359.CrossRefPubMed
11.
go back to reference Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, Vijaykrishna D, Zhang JX, Zhang LJ, Guo CT, et al: Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. Proc Natl Acad Sci USA. 2006, 103: 2845-2850. 10.1073/pnas.0511120103.PubMedCentralCrossRefPubMed Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, Vijaykrishna D, Zhang JX, Zhang LJ, Guo CT, et al: Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. Proc Natl Acad Sci USA. 2006, 103: 2845-2850. 10.1073/pnas.0511120103.PubMedCentralCrossRefPubMed
12.
go back to reference Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG: Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA. 2005, 102: 12915-12920. 10.1073/pnas.0506416102.PubMedCentralCrossRefPubMed Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG: Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA. 2005, 102: 12915-12920. 10.1073/pnas.0506416102.PubMedCentralCrossRefPubMed
13.
go back to reference Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, Ostell J, Lipman D: The Influenza Virus Resource at the National Center for Biotechnology Information. J Virol. 2008, 82: 596-601. 10.1128/JVI.02005-07.PubMedCentralCrossRefPubMed Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, Ostell J, Lipman D: The Influenza Virus Resource at the National Center for Biotechnology Information. J Virol. 2008, 82: 596-601. 10.1128/JVI.02005-07.PubMedCentralCrossRefPubMed
14.
go back to reference Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA: Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006, 312: 404-410. 10.1126/science.1124513.CrossRefPubMed Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA: Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006, 312: 404-410. 10.1126/science.1124513.CrossRefPubMed
15.
go back to reference Brown LE, Murray JM, White DO, Jackson DC: An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin. Arch Virol. 1990, 114: 1-26. 10.1007/BF01311008.CrossRefPubMed Brown LE, Murray JM, White DO, Jackson DC: An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin. Arch Virol. 1990, 114: 1-26. 10.1007/BF01311008.CrossRefPubMed
16.
go back to reference Szecsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, Klenk HD, Klatzmann D, Volchkov V, Cosset FL: Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J. 2006, 3: 70-10.1186/1743-422X-3-70.PubMedCentralCrossRefPubMed Szecsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, Klenk HD, Klatzmann D, Volchkov V, Cosset FL: Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J. 2006, 3: 70-10.1186/1743-422X-3-70.PubMedCentralCrossRefPubMed
17.
go back to reference Kolokoltsov AA, Wang E, Colpitts TM, Weaver SC, Davey RA: Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. Am J Trop Med Hyg. 2006, 75: 702-709.PubMed Kolokoltsov AA, Wang E, Colpitts TM, Weaver SC, Davey RA: Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. Am J Trop Med Hyg. 2006, 75: 702-709.PubMed
18.
go back to reference Kolokoltsov AA, Weaver SC, Davey RA: Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J Virol. 2005, 79: 756-763. 10.1128/JVI.79.2.756-763.2005.PubMedCentralCrossRefPubMed Kolokoltsov AA, Weaver SC, Davey RA: Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J Virol. 2005, 79: 756-763. 10.1128/JVI.79.2.756-763.2005.PubMedCentralCrossRefPubMed
Metadata
Title
Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1
Authors
Angeline PC Lim
Steven KK Wong
Annie HY Chan
Conrad EZ Chan
Eng Eong Ooi
Brendon J Hanson
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2008
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-5-80

Other articles of this Issue 1/2008

Virology Journal 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.